Tempus AI Study Highlights Benefits of Dual RNA and DNA Sequencing for Advanced Lung Cancer

Ontada and Datavant Partner to Expand Access to Real-World Oncology Data for Accelerated Cancer Innovation

Tempus AI and Flatiron Health Partner to Integrate Genomic Testing into OncoEMR for Enhanced Oncology Care

Flare Therapeutics and Roche Forge Strategic Partnership to Discover Precision Oncology Therapies Targeting Transcription Factors

FDA Approves Autolus’s CAR-T Therapy Aucatzyl for Relapsed or Refractory B-ALL in Adults

Biosimilars: Expanding Access to Precision Medicine through Affordable Biologic Therapies

IDEAYA Biosciences Secures Exclusive Worldwide License for Biocytogen’s BsADC Program IDE034 for Solid Tumor Treatment

Seer and Thermo Fisher Scientific Announce Strategic Collaboration to Advance Proteomics with Integrated Platform Solution

SystImmune Secures FDA Clearance for IND Application of Novel ADC Therapy BL-M17D1 for Advanced Solid Tumors

Medicare Expands Coverage for Adaptive Biotechnologies' clonoSEQ® MRD Test to Include Mantle Cell Lymphoma

Illumina and PHASE Partner to Advance Oncology Testing in the Greater Bay Area, Supporting the "Healthy China" Initiative

MGI Partners with Human Cell Atlas to Advance Global Human Cell Mapping

NHS Wales and Illumina Expand Partnership to Advance Genomic Cancer Detection and Personalized Medicine

Unlocking Genomic Potential for Rare Cancers: Cancer52 and Genomics England’s Collaborative Approach

Tempus AI Launches Immune Profile Score to Enhance Precision in Immunotherapy for Advanced Cancer Patients

Home
/
update
/
details

Seer and Thermo Fisher Scientific Announce Strategic Collaboration to Advance Proteomics with Integrated Platform Solution

NextEdge Admin

11 Nov 2024

2 min 0 sec

Seer, Inc. (Nasdaq: SEER), a leader in life sciences, announced a co-marketing and sales agreement with Thermo Fisher Scientific to promote Seer’s Proteograph™ Product Suite alongside Thermo Scientific’s Orbitrap Astral™ mass spectrometers. This collaboration aims to accelerate proteomic research by offering a comprehensive, high-throughput solution for unbiased, deep proteomic analysis.

Under this non-exclusive agreement, Thermo Fisher’s global sales team will now be able to quote and sell Seer’s Proteograph Product Suite, which includes an automation instrument, engineered nanoparticles, and software suite. The combined platforms, available in early 2025, enhance the accessibility of cutting-edge proteomic tools to researchers worldwide. Together, Seer and Thermo Fisher will conduct joint marketing activities, including webinars and seminars, to demonstrate the synergistic benefits of their technologies.

“This partnership is a pivotal step in making transformative proteomics widely accessible by combining our Proteograph suite with Thermo Fisher’s Orbitrap Astral mass spectrometers,” said Omid Farokhzad, Seer’s CEO and Chair. Thermo Fisher’s John Lesica added, “Aligning our technologies provides customers a powerful solution for proteomic insights, fostering breakthroughs in biology and disease research.”

The companies will continue joint research efforts to improve workflows and validate the benefits of their integrated platforms in large-scale studies, further advancing the proteomics field.